Molecular Biology Testing in NSCLC
- CME / AMA PRA Category 1 Credit™
- MOC / ABIM MOC Part 2 Credit
- MIPS Improvement Activity Under MACRA
PROGRAM OVERVIEW
This adaptive-learning module will provide participants with a comprehensive review of the role of molecular testing in the decision-making process for patients with non-small cell lung cancer (NSCLC). Various methods of molecular testing will be discussed.
AGENDA
Molecular Testing Targets
TARGET AUDIENCE
This activity is intended for oncologists and other healthcare professionals involved in the treatment and care of patients with lung cancer.
EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Utilize molecular testing to help guide treatment decisions for patients with advanced NSCLC
- Evaluate the updated clinical guidelines for first-line treatment of advanced NSCLC
ACCREDITATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
The Potomac Center for Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit or the evaluation, please email contact@potomacme.org.
FACULTY

Ingram Associate Professor of Cancer Research
Director, Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt Ingram Cancer Center
Nashville, TN

Assistant Professor
Associate Director, Surgical Pathology Fellowship
Pathology, Microbiology and Immunology
Vanderbilt University Medical Center
Nashville, TN
ABIM MOC DESIGNATION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
MOC APPROVAL STATEMENT
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, Molecular Biology Testing in NSCLC has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:
MOC Part II CME Activity
Internal Medicine
MOC Part II CME Activity
Family Medicine
Medical Genetics and Genomics
https://www.continuingcertification.org/activity/molecular-biology-testing-in-nsclc/
MIPS CREDIT DESIGNATION
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
DISCLOSURES
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. Disclosures will be made known to the participants prior to the activity.
The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.
Faculty, Authors and Content Developers
The faculty, authors and content developers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Leora Horn, MD, MSc, FRCPC: Consultant/Independent Contractor: AstraZeneca, Amgen, Bayer, EMD Serono, Incyte, Merck, Pfizer, Xcovery; Grant/Research Support: Bristol-Myers Squibb, Boehringer Ingelheim, Xcovery
Mitra Mehrad, MD: Nothing to disclose
Josh Kilbridge: Nothing to disclose
Planners and Managers
The planners and manger reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Chelsey Goins, PhD; Joanne M. Fayal; Blair St. Amand: Nothing to disclose
Content Reviewers
The content reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Katie Propst, PhD; Lindsay Scott, PT, DPT, ATC: Nothing to disclose
FDA DISCLOSURE
SYSTEM REQUIREMENTS
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT
PROVIDER
Jointly provided by the Potomac Center for Medical Education and Rockpointe
SUPPORTER
This activity is not supported by any grantor or commercial interest.
RELATED COURSES

X-Linked Hypophosphatemia: Improving Clinician Awareness and Management
Credits 1.00 (60 min)
Format Webcourse


Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS) and the New FDA Blueprint
Credits 3.00 (3 hrs)
Format Webcourse
Feb